Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 13/20 | 0.44 |
| ▸ | JAK3 | P52333 | 2/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.43 |
| ▸ | AKT1 | P31749 | 6/20 | 0.43 |
| ▸ | AKT3 | Q9Y243 | 3/20 | 0.43 |
| ▸ | PRKACA | P17612 | 2/20 | 0.43 |
| ▸ | PRKACG | P22612 | 2/20 | 0.43 |
| ▸ | PRKACB | P22694 | 2/20 | 0.43 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.43 |
| ▸ | LIMK2 | P53671 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3490469 | 0.91 | AKT2 (0.45) | AKT2JAK3ROCK2AKT1AKT3 | |
| SCHEMBL3490511 | 0.90 | ROCK2 (0.42) | ROCK2AKT1PRKACAPRKACGPRKACB | |
| SCHEMBL3490615 | 0.89 | CNR1 (0.37) | ROCK2PRKACAPRKACGPRKACBLIMK1 | |
| SCHEMBL3490474 | 0.83 | JAK3 (0.45) | AKT2JAK3ROCK2AKT1AKT3 | |
| SCHEMBL3491436 | 0.80 | ROCK2 (0.43) | ROCK2AKT1PRKACAPRKACGPRKACB | |
| SCHEMBL3490306 | 0.80 | CNR1 (0.36) | ROCK2AKT1PRKACAPRKACGPRKACB | |
| SCHEMBL31374403 | 0.79 | JAK3 (0.58) | AKT2JAK3ROCK2AKT1AKT3 | |
| SCHEMBL390884 | 0.79 | JAK3 (0.58) | AKT2JAK3ROCK2AKT1AKT3 | |
| SCHEMBL3489441 | 0.79 | AKT2 (0.47) | AKT2JAK3ROCK2AKT1AKT3 | |
| SCHEMBL3489790 | 0.79 | AKT1 (0.48) | AKT2JAK3ROCK2AKT1AKT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | PRKAR2B, GRK3, PRKAR2A | AKT2 35/4885JAK3 225/4885ROCK2 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.